Chongqing Pharscin Pharmaceutical Co Ltd (002907) - Total Assets

Latest as of September 2025: CN¥2.00 Billion CNY ≈ $292.33 Million USD

Based on the latest financial reports, Chongqing Pharscin Pharmaceutical Co Ltd (002907) holds total assets worth CN¥2.00 Billion CNY (≈ $292.33 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 002907 book value for net asset value and shareholders' equity analysis.

Chongqing Pharscin Pharmaceutical Co Ltd - Total Assets Trend (2013–2024)

This chart illustrates how Chongqing Pharscin Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data.

Chongqing Pharscin Pharmaceutical Co Ltd - Asset Composition Analysis

Current Asset Composition (December 2024)

Chongqing Pharscin Pharmaceutical Co Ltd's total assets of CN¥2.00 Billion consist of 53.8% current assets and 46.2% non-current assets.

Asset Category Amount (CNY) % of Total Assets
Cash & Equivalents CN¥0.00 23.8%
Accounts Receivable CN¥275.60 Million 14.4%
Inventory CN¥140.12 Million 7.3%
Property, Plant & Equipment CN¥0.00 0.0%
Intangible Assets CN¥156.16 Million 8.1%
Goodwill CN¥0.00 0.0%

Asset Composition Trend (2013–2024)

This chart illustrates how Chongqing Pharscin Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Chongqing Pharscin Pharmaceutical Co Ltd stock valuation.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Chongqing Pharscin Pharmaceutical Co Ltd's current assets represent 53.8% of total assets in 2024, a decrease from 53.8% in 2013.
  • Cash Position: Cash and equivalents constituted 23.8% of total assets in 2024, up from 7.4% in 2013.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, an increase from 7.0% in 2013.
  • Asset Diversification: The largest asset category is accounts receivable at 14.4% of total assets.

Chongqing Pharscin Pharmaceutical Co Ltd Competitors by Total Assets

Key competitors of Chongqing Pharscin Pharmaceutical Co Ltd based on total assets are shown below.

Company Country Total Assets
Changchun High & New Technology Industries Group Inc
SHE:000661
China CN¥31.46 Billion
Yuhan Corp.
KO:000100
Korea ₩3.05 Trillion
Tasly Pharmaceutical Group Co Ltd
SHG:600535
China CN¥15.34 Billion
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
China CN¥15.32 Billion
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
China CN¥10.96 Billion
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
China CN¥1.54 Billion
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
China CN¥6.74 Billion
Cronos Group Inc
TO:CRON
Canada CA$1.18 Billion

Chongqing Pharscin Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 4.66 4.89 3.48
Quick Ratio 4.13 4.17 3.01
Cash Ratio 0.00 0.00 0.00
Working Capital CN¥855.56 Million CN¥806.45 Million CN¥633.21 Million

Chongqing Pharscin Pharmaceutical Co Ltd - Advanced Valuation Insights

This section examines the relationship between Chongqing Pharscin Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 3.62
Latest Market Cap to Assets Ratio 0.44
Asset Growth Rate (YoY) 3.6%
Total Assets CN¥1.92 Billion
Market Capitalization $852.45 Million USD

Valuation Analysis

Below Book Valuation: The market values Chongqing Pharscin Pharmaceutical Co Ltd's assets below their book value (0.44x), which may indicate investor concerns about asset quality or future growth.

Positive Asset Growth: Chongqing Pharscin Pharmaceutical Co Ltd's assets grew by 3.6% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for Chongqing Pharscin Pharmaceutical Co Ltd (2013–2024)

The table below shows the annual total assets of Chongqing Pharscin Pharmaceutical Co Ltd from 2013 to 2024.

Year Total Assets Change
2024-12-31 CN¥1.92 Billion
≈ $280.60 Million
+3.57%
2023-12-31 CN¥1.85 Billion
≈ $270.93 Million
-0.81%
2022-12-31 CN¥1.87 Billion
≈ $273.15 Million
+5.37%
2021-12-31 CN¥1.77 Billion
≈ $259.22 Million
+2.91%
2020-12-31 CN¥1.72 Billion
≈ $251.90 Million
+5.13%
2019-12-31 CN¥1.64 Billion
≈ $239.61 Million
+49.73%
2018-12-31 CN¥1.09 Billion
≈ $160.03 Million
+23.55%
2017-12-31 CN¥885.15 Million
≈ $129.52 Million
+35.69%
2016-12-31 CN¥652.32 Million
≈ $95.46 Million
+20.96%
2015-12-31 CN¥539.29 Million
≈ $78.92 Million
+0.35%
2014-12-31 CN¥537.39 Million
≈ $78.64 Million
+29.38%
2013-12-31 CN¥415.35 Million
≈ $60.78 Million
--

About Chongqing Pharscin Pharmaceutical Co Ltd

SHE:002907 China Drug Manufacturers - Specialty & Generic
Market Cap
$852.45 Million
CN¥5.83 Billion CNY
Market Cap Rank
#9841 Global
#2783 in China
Share Price
CN¥13.95
Change (1 day)
+0.14%
52-Week Range
CN¥12.88 - CN¥21.87
All Time High
CN¥42.89
About

Chongqing Pharscin Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of drugs in China. The company offers tablets, powders, granules, soft capsules, powder injections, freeze-dried powders, injections, chemical raw materials, and small volume injections. It provides its products for the treatment of CNS, digestion, otolaryngology, oncology, cardiovascular, an… Read more